EMEA-001741-PIP04-17-M02
Key facts
| Invented name |
Rinvoq
|
| Active substance |
upadacitinib
|
| Therapeutic area |
|
| Decision number |
P/0166/2021
|
| PIP number |
EMEA-001741-PIP04-17-M02
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of atopic dermatitis
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
AbbVie Ltd
E-mail: paediatricteam@abbvie.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|